The role of interleukin-33 in pathogenesis of bronchial asthma. New experimental data
- Авторлар: Khaitov M.1, Gaisina A.1, Shilovskiy I.1, Smirnov V.1,2, Ramenskaia G.2, Nikonova A.1,3, Khaitov R.1
-
Мекемелер:
- Institute of Immunology
- Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation
- Mechnikov Research Institute for Vaccines and Sera
- Шығарылым: Том 83, № 1 (2018)
- Беттер: 13-25
- Бөлім: Review
- URL: https://journals.rcsi.science/0006-2979/article/view/151563
- DOI: https://doi.org/10.1134/S0006297918010029
- ID: 151563
Дәйексөз келтіру
Аннотация
Interleukin-33 (IL-33) belongs to the IL-1 cytokine family and plays an important role in modulating immune system by inducing Th2 immune response via the ST2 membrane receptor. Epithelial cells are the major producers of IL-33. However, IL-33 is also secreted by other cells, e.g., bone marrow cells, dendritic cells, macrophages, and mast cells. IL-33 targets a broad range of cell types bearing the ST2 surface receptor. Many ST2-positive cells, such as Th2 cells, mast cells, basophils, and eosinophils, are involved in the development of allergic bronchial asthma (BA). This suggests that IL-33 directly participates in BA pathogenesis. Currently, the role of IL-33 in pathogenesis of inflammatory disorders, including BA, has been extensively investigated using clinical samples collected from patients, as well as asthma animal models. In particular, numerous studies on blocking IL-33 and its receptor by monoclonal antibodies in asthma mouse model have been performed over the last several years; IL-33-and ST2-deficient transgenic mice have also been generated. In this review, we summarized and analyzed the data on the role of IL-33 in BA pathogenesis and the prospects for creating new treatments for BA.
Негізгі сөздер
Авторлар туралы
M. Khaitov
Institute of Immunology
Email: ip.shilovsky@nrcii.ru
Ресей, Moscow, 115478
A. Gaisina
Institute of Immunology
Email: ip.shilovsky@nrcii.ru
Ресей, Moscow, 115478
I. Shilovskiy
Institute of Immunology
Хат алмасуға жауапты Автор.
Email: ip.shilovsky@nrcii.ru
Ресей, Moscow, 115478
V. Smirnov
Institute of Immunology; Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation
Email: ip.shilovsky@nrcii.ru
Ресей, Moscow, 115478; Moscow, 119991
G. Ramenskaia
Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation
Email: ip.shilovsky@nrcii.ru
Ресей, Moscow, 119991
A. Nikonova
Institute of Immunology; Mechnikov Research Institute for Vaccines and Sera
Email: ip.shilovsky@nrcii.ru
Ресей, Moscow, 115478; Moscow, 105064
R. Khaitov
Institute of Immunology
Email: ip.shilovsky@nrcii.ru
Ресей, Moscow, 115478